With respect to immune biomarkers of response for HNSCC undergoing treatment with radiotherapy or chemoradiotherapy, infiltration of CD3 lymphocytes in the tumor microenvironment and PD-L1 expression on tumor cells or immune cells have separately showed prognostic correlation with survival outcomes or response to radiotherapy (78, 79). The gene discussed is CD274; the disease is neoplasm.